[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-56408-en":3,"doc-seo-56408-105":28,"detail-sidebar-cat-0-en-105":92},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":20,"language":21,"language_code":22,"site_id":23,"html_lang":22,"table_of_contents":24,"faqs":25,"seo_title":13,"seo_description":14,"update_tm":26,"read_time":27},56408,1099513958607,"Jiven","https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399",8,"Research & Report","Assessment of Combination Therapies Versus Phosphodiesterase Type 5 Inhibitor Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-Analysis","A systematic review and meta-analysis evaluates the efficacy and safety of combination therapies that include phosphodiesterase type 5 inhibitors (PDE5i) against PDE5i monotherapy for men with erectile dysfunction across patient subgroups. Randomized trials using validated questionnaires were pooled, focusing on mean change in the International Index of Erectile Function (IIEF) and treatment-related adverse events. Combination therapy improved IIEF by 1.92 points and did not increase adverse events versus monotherapy. Benefits varied by add-on modality, while heterogeneity remained high.","Proceedings of the 22nd World Meeting of the ISSM S125  \nEach participant underwent sexual stimulation sessions in adequate privacy, wherein the audio-visual stimuli as well as stimulation by their heterosexual partner were used for sexual arousal. Following this, they masturbated, which began after reaching the level seven of Mosher’s scale of genital sensations, which is the highest point of sexual arousal prior to reaching orgasm. Their heart rate was monitored throughout the session, which was recorded using digital pulse oxymeter. This was taken as additional objective biological evidence to record highest point of arousal. The heterosexual partner’s opinion with regard to increase in size of glans as well as increased pulsations in penis was also taken into account to record the highest point of arousal, which was an additional crosscheck mechanism. The time from the highest point of sexual arousal to the point at which the study participant expressed inability to hold ejaculation to any further point of time was recorded using stopwatch by the investigator as the HoT. The test was repeated after 6 weeks to assess test-retest reliability, which was measured using Pearson’scoefficient (r) . Correlations between PEDT diagnosed PE and self-reported PE, with stopwatch measured HoT was assessed to validate HoT.  \nResults: Ten healthy controls (Mean age 30.3§4.64 years) and ten volunteers with self-reported PE (Mean age 29.6§4.25 years) participated in the study conducted from May 2020 to April 2021 . The mean stopwatch measured HoT in seconds, recorded by healthy volunteers and self-reported PE were 119.6§33.6 and 32.4§ 12.8 respectively. Test-retest reliability was good for both the healthy volunteers (r =0.983) and volunteers with PE (r =0.839) . It had a sensitivity of 90% and specificity of 91% for diagnosis of PE. The positive predictive value was 79.4% and negative predictive value was 95.5% . Excellent correlations between PEDT and HoT with respect to the diagnosis of PE demonstrated construct validity of HoT.  \nConclusions: The development of an objective tool to evaluate the control over ejaculation helps to develop more objective definition and better management of ejaculatory dysfunctions in males. As per preliminary validation data, Holding Time (HoT) is a reliable objective tool to measure control over ejaculation in males.  \nDisclosure: Work supported by industry: no.  \nPictorial depiction of Holding Time (HoT) in a sexual response cycle  \n005  \nASSESSMENT OF COMBINATION THERAPIES VERSUS PHOSPHODIESTERASE TYPE 5 INHIBITOR MONOTHERAPY FOR ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS  \nMykoniatis, I.1; Pyrgidis, N.2; Sokolakis, I.2; Ouranidis, A.1; Sountoulides, P.1; Haidich, A.1; Van Renterghem, K.3; Hatzichristodoulou, G.2; Hatzichristou, D.1  \n1Aristotle University of Thessaloniki; 2Martha-Maria Hospital, Nuremberg Germany; 3 University Hospitals Leuven  \nIntroduction: Combining two first-line treatments for erectile dysfunction (ED) or initiating other effective modalities on top of phosphodiesterase type 5 inhibitors (PDE5i) may produce beneficial outcomes.  \nObjective: To assess the efficacy and safety of different combination therapies with PDE5i compared to PDE5i monotherapy in various subgroups of patients with ED through a systematic review and meta-analysis.  \nMethods: We considered randomized trials on males with ED that assessed the effect of combination therapy versus PDE5i monotherapy with validated questionnaires. Studies were identified by searching Medline, Cochrane Library and Scopus databases We undertook a meta-analysis for the mean international index of erectile function (IIEF) change, and for the number of adverse events (AEs) based on different treatment modalities and subgroups of patients.  \nResults: We included 3,853 individuals (44 trials) . Combination therapy with PDE5i, compared to PDE5i monotherapy, was associated with a mean IIEF improvement of 1 .92 points (95% CI: 1 .41 ","cbCaiinwpRzhDsde","https://ap.wps.com/l/cbCaiinwpRzhDsde","pdf",196973,1,"English","en",105,"# Introduction\n## Objective\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What comparison does the meta-analysis evaluate for erectile dysfunction?\",\"answer\":\"It compares combination therapies involving PDE5 inhibitors versus PDE5 inhibitor monotherapy in men with erectile dysfunction, using results from randomized trials.\"},{\"question\":\"Which outcomes are used to measure effectiveness and safety?\",\"answer\":\"Effectiveness is assessed using mean change in IIEF, and safety is assessed by the number of adverse events across treatment modalities and subgroups.\"},{\"question\":\"Does combination therapy increase adverse events compared with monotherapy?\",\"answer\":\"No. Treatment-related adverse events did not differ between combination treatment with PDE5i and PDE5i monotherapy (reported OR around 1.10 with confidence intervals crossing 1).\"},{\"question\":\"Which patient subgroups may benefit most from combination therapy?\",\"answer\":\"The report indicates improved IIEF with combination treatment for patients with hypogonadism, monotherapy-resistant cases, or prostatectomy-induced erectile dysfunction, while adding alpha-blockers did not add efficacy for patients with urinary symptoms.\"}]",1783890049,3,{"code":4,"msg":29,"data":30},"ok",{"site_id":23,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":87,"head_meta":89,"extra_data":91,"updated_unix":26},"assessment-of-combination-therapies-versus-phosphodiesterase-type-5-inhibitor-monotherapy-for-erectile-dysfunction-a-systematic-review-and-meta-analysis","",{"@graph":34,"@context":86},[35,51,65],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,48],{"item":39,"name":40,"@type":41,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":27},"https://docshare.wps.com/document/research-report/",{"item":49,"name":13,"@type":41,"position":50},"https://docshare.wps.com/document/assessment-of-combination-therapies-versus-phosphodiesterase-type-5-inhibitor-monotherapy-for-erectile-dysfunction-a-systematic-review-and-meta-analysis/56408/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"inLanguage":22,"description":14,"dateModified":59,"datePublished":59,"encodingFormat":58,"isAccessibleForFree":60,"interactionStatistic":61},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":39,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-07-12",true,{"@type":62,"interactionType":63,"userInteractionCount":4},"InteractionCounter",{"@type":64},"ViewAction",{"@type":66,"mainEntity":67},"FAQPage",[68,74,78,82],{"name":69,"@type":70,"acceptedAnswer":71},"What comparison does the meta-analysis evaluate for erectile dysfunction?","Question",{"text":72,"@type":73},"It compares combination therapies involving PDE5 inhibitors versus PDE5 inhibitor monotherapy in men with erectile dysfunction, using results from randomized trials.","Answer",{"name":75,"@type":70,"acceptedAnswer":76},"Which outcomes are used to measure effectiveness and safety?",{"text":77,"@type":73},"Effectiveness is assessed using mean change in IIEF, and safety is assessed by the number of adverse events across treatment modalities and subgroups.",{"name":79,"@type":70,"acceptedAnswer":80},"Does combination therapy increase adverse events compared with monotherapy?",{"text":81,"@type":73},"No. Treatment-related adverse events did not differ between combination treatment with PDE5i and PDE5i monotherapy (reported OR around 1.10 with confidence intervals crossing 1).",{"name":83,"@type":70,"acceptedAnswer":84},"Which patient subgroups may benefit most from combination therapy?",{"text":85,"@type":73},"The report indicates improved IIEF with combination treatment for patients with hypogonadism, monotherapy-resistant cases, or prostatectomy-induced erectile dysfunction, while adding alpha-blockers did not add efficacy for patients with urinary symptoms.","https://schema.org",{"og:url":49,"og:type":88,"og:title":13,"og:site_name":56,"og:description":14},"article",{"robots":90,"canonical":49},"index,follow",{"doc_id":7,"site_id":23},{"code":4,"msg":5,"data":93},[94,98,102,106,111,116,121,124,129,132,136],{"id":20,"doc_module":4,"doc_module_name":44,"category_name":95,"show_sort_weight":96,"slug":97},"Story & Novel",90,"story-novel",{"id":45,"doc_module":4,"doc_module_name":44,"category_name":99,"show_sort_weight":100,"slug":101},"Literature",80,"literature",{"id":50,"doc_module":4,"doc_module_name":44,"category_name":103,"show_sort_weight":104,"slug":105},"Exam",70,"exam",{"id":107,"doc_module":4,"doc_module_name":44,"category_name":108,"show_sort_weight":109,"slug":110},5,"Comic",60,"comic",{"id":112,"doc_module":4,"doc_module_name":44,"category_name":113,"show_sort_weight":114,"slug":115},6,"Technology",50,"technology",{"id":117,"doc_module":4,"doc_module_name":44,"category_name":118,"show_sort_weight":119,"slug":120},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":44,"category_name":12,"show_sort_weight":122,"slug":123},30,"research-report",{"id":125,"doc_module":4,"doc_module_name":44,"category_name":126,"show_sort_weight":127,"slug":128},9,"Religion & Spirituality",20,"religion-spirituality",{"id":127,"doc_module":4,"doc_module_name":44,"category_name":130,"show_sort_weight":127,"slug":131},"World Cup","world-cup",{"id":133,"doc_module":4,"doc_module_name":44,"category_name":134,"show_sort_weight":133,"slug":135},10,"Lifestyle","lifestyle",{"id":137,"doc_module":4,"doc_module_name":44,"category_name":138,"show_sort_weight":107,"slug":139},19,"General","general"]